Compare PLSE & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | ARDX |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2015 | 2014 |
| Metric | PLSE | ARDX |
|---|---|---|
| Price | $23.02 | $5.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $22.00 | $15.14 |
| AVG Volume (30 Days) | 217.2K | ★ 3.0M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | $840.00 | $37.75 |
| Revenue Next Year | $287.54 | $34.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.56 | $3.50 |
| 52 Week High | $26.30 | $8.40 |
| Indicator | PLSE | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 55.70 | 45.34 |
| Support Level | $13.62 | $5.49 |
| Resistance Level | $23.42 | $6.23 |
| Average True Range (ATR) | 1.53 | 0.24 |
| MACD | 0.33 | -0.01 |
| Stochastic Oscillator | 71.51 | 25.31 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.